Home > Journals > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Past Issues > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2020 December;179(12) > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2020 December;179(12):657-64

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2020 December;179(12):657-64

DOI: 10.23736/S0393-3660.20.04452-6

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: Italian

Low dose diclofenac: safer and more effective

Beniamino PALMIERI 1, 2, 3, Maria VADALÀ 1, 2, 3 , Raffaele LUCÀ 3, Anna ASPIRO 3, Erio BARBIERI 3, 4, Raffaello IMBROGNO 3, 5, Andrea GARELLI 3, 6, Paolo MILAN 3, 7, Giovanni LAZZARONI 3, 8, Michele MELCHIONDA 3, 9, Lucia PALMIERI 3, 10

1 Department of Surgical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy; 2 Second Opinion Medical Consulting Network, Modena, Italy; 3 Medico Cura Te Stesso Onlus, Modena, Italy; 4 AUSL Modena, Modena, Italy; 5 AUSL Modena, Sassuolo, Modena, Italy; 6 Department of Plastic and Reconstructive Surgery, Casilino Polyclinic, Rome, Italy; 7 Medical Center, Noale, Venice, Italy; 8 Medical Center, Borgo San Giacomo, Brescia, Italy; 9 AUSL Modena, Rovarino, Modena, Italy; 10 Nephrology, Dialysis and Transplantation Complex Structure, Polyclinic of Modena, Modena, Italy



BACKGROUND: The non-steroid anti-inflammatory drugs (NSAIDs) are widely used despite the well-known cardiovascular, gastrointestinal and kidney side effects. Aim of the present study was to evaluate the safety and effectiveness of new low dosage (12.5 mg) diclofenac formula on patients referring to our Second Opinion Medical Consulting Network (Modena, Italy), because of different kinds of acute and chronic pain, unsuccessfully treated with long term full dosage NSAIDs use, with different administration schedules; the switch to low dose diclofenac was intended to reduce the risk of the side effects, achieving a good control of inflammation and pain.
METHODS: Five-hundred patients both sexes, aged between 18 and 95 years, at the same time affected by chronic pain, with periodic, regular use of anti-inflammatory drugs on the market turned to Second Opinion Medical Network. We visited and prescribed 1-3 soft gel cps of Flectorgo® dose up to a maximum dosage of 37.5 mg/day for no more than 3 days.
RESULTS: In this cohort of patients a very quick molecule bioavailability achieved meaning full pain relieve excellent tolerability and absence of severe side effects.
CONCLUSIONS: This spontaneous anecdotical Second Opinion clinical study confirms the effectiveness and benefits of low dose diclofenac administration. Further observations are needed about the safety of subcontinuous or continuous low dose schedule, the customers satisfaction and family doctor’s awareness about the advantages of this new low dose formulation in comparison with the higher concentration of NSAIDs molecules currently prescribed.


KEY WORDS: Diclofenac; Pain; Anti-inflammatory agents, non-steroidal

top of page